Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Telo Genomics Corp TDSGF


Primary Symbol: V.TELO

Healthcare Industrials Biotechnology Conglomerates
Telo Genomics Corp. is a Canada-based biotech company. The Company is focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions. The Company, through its wholly owned subsidiary, Telo Genomics Holdings Corp., is developing diagnostic and prognostic products for diseases that display... see more

Recent & Breaking News (TSXV:TELO)

Telo Genomics Receives Accreditation from College of American Pathologists

Newsfile April 10, 2024

Telo Genomics' Flagship MRD Clinical Trial Expands into Multi-Center Trial

Newsfile April 2, 2024

Telo Genomics kick-starts clinical trial for multiple myeloma patients

Jocelyn Aspa February 13, 2024

Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients

Newsfile February 13, 2024

Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the US

Newsfile January 30, 2024

Telo Genomics Gears up for American Society of Hematology Conference

Newsfile December 6, 2023

Telo Genomics launches physician-based cancer program in U.S.

Jocelyn Aspa November 16, 2023

Telo Genomics Launches Physician Experience Program in the United States

Newsfile November 16, 2023

Telo Genomics Advances to the Final Stage of Accreditation from The College of American Pathologists

Newsfile November 7, 2023

American Society of Hematology (ASH) Accepts Validation Data from Telo Genomics for Presentation at Upcoming Annual Meeting

Newsfile November 1, 2023

Telo Genomics Completes International Standards Organization ("ISO") 15189 Final Accreditation

Newsfile October 26, 2023

Telo Genomics launches cancer diagnostic platform in the U.S.

Jocelyn Aspa October 17, 2023

Telo Genomics Announces Clinical Launch of Non-Invasive Cancer Diagnostic, TeloViewSMM - An Important Commercial Milestone Achieved

Newsfile October 17, 2023

Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting

Newsfile October 12, 2023

Telo Genomics Achieves Noteworthy International Standards Organization ("ISO") Regulatory Accreditation

Newsfile September 6, 2023

Telo Genomics Reports Substantial Progress Toward Clinical Launch of TeloView-SMM

Newsfile August 29, 2023

Telo Genomics Announces Agreement for Strategic Advisory Services

Newsfile June 30, 2023

Telo Genomics Completes Oversubscribed Private Placement

Newsfile June 14, 2023

Telo Genomics Presents Positive Data in Newly Diagnosed Multiple Myeloma Drug Resistance Study at EHA 2023

Newsfile June 12, 2023

Telo Genomics Announces Private Placement Increased to $2,766,375 from Previously Announced Private Placement of $2,000,000

Newsfile June 6, 2023